Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Shaw, Alice T

Class:Id	Person:9700355
_displayName	Shaw, Alice T
_timestamp	2020-09-16 05:14:53
created	[InstanceEdit:9700359] Rothfels, Karen, 2020-09-16
firstname	Alice T
initial	AT
surname	Shaw
(author)	[LiteratureReference:9700343] Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK [LiteratureReference:9700350] The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer [LiteratureReference:9701740] Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers [LiteratureReference:9702216] Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial [LiteratureReference:9702243] Ceritinib in ALK-rearranged non-small-cell lung cancer [LiteratureReference:9713864] ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials [LiteratureReference:9713917] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer [LiteratureReference:9714001] Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer [LiteratureReference:9715259] Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib [LiteratureReference:9717312] Targeting ALK: Precision Medicine Takes on Drug Resistance
[Change default viewing format]

No pathways have been reviewed or authored by Shaw, Alice T (9700355)